Liu Yong

Research areas: Diagnosis and treatment of spinal, pelvic, and limb bone and soft tissue tumors, functional reconstruction and limb-sparing surgery; minimally invasive surgical treatment of metastatic cancer of the spine and limbs; surgical treatment of metabolic bone diseases such as neoplastic hypophosphatemic osteomalacia.

Cutting-edge technology: One of the first batch of medical and science doctoral degree holders trained independently in my country, he successfully isolated and cultured three SARS coronavirus strains of the PUMC series, one of which was identified as a national vaccine strain. In the field of standardized comprehensive treatment of bone tumors, he is proficient in limb-sparing surgery and functional reconstruction for malignant bone tumors such as osteosarcoma, and has demonstrated outstanding technical capabilities in complex surgeries of spinal, pelvic, and limb tumors.

Diseases specializing in: primary malignant bone tumors such as osteosarcoma, chondrosarcoma, and Ewing sarcoma; spinal metastases; pelvic tumors; neoplastic hypophosphatemic osteomalacia (TIO); and benign tumors of bone and soft tissue.

Academic Highlights and Core Values: Chief Physician of Orthopedics, Professor, and Master's Supervisor. Member of the Bone Tumor Group of the Chinese Orthopaedics Branch of the Chinese Medical Association, and Standing Committee Member of the Bone Tumor Committee of the Chinese Division of the International Society of Orthopaedic and Traumatology (SICTO). Published over 0 SCI papers as first/corresponding author, over 20 papers in Chinese core journals, and obtained 15 utility model patents. Participated in multiple National 3D Program and National Natural Science Foundation of China projects. The team received the Second Prize for Medical Research Achievements from Peking Union Medical College Hospital. Professor Liu Yong's focused dedication to the field of bone tumors is the core driving force behind the professional group's academic culture and clinical capabilities.